Pure Global
NCT06387342

Namodenoson Treatment of Advanced Pancreatic Cancer

CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma
Can-Fite BioPharma·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pancreatic Adenocarcinoma,Pancreatic Cancer
Drug/Device/Intervention
Namodenoson 25mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Can-Fite BioPharma
Location
Petach Tikva, Israel
Timeline & enrollment
Phase
Phase 2
Start date
Jul 15, 2024
End date
Dec 15, 2026
Enrollment
20 participants
Primary outcome

Adverse Events,Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline

Summary

This is an open-label trial in patients with advanced pancreatic cancer. The trial will
 evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson,
 in this group of patients.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Other parts of pancreasMalignant neoplasm: Tail of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06387342
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06387342 through Pure Global AI's free database. This Phase 2 trial is sponsored by Can-Fite BioPharma and is currently Not yet recruiting. The study focuses on Pancreatic Adenocarcinoma,Pancreatic Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.